Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
前收盘价
US$72.46
+US$0.01 · +0.01%
盘中时间采用ET。市场数据可能有所延迟。
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
日内区间
当前US$72.46
52周区间
当前US$72.46
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
48
合理估值
情绪
58
多空交织
风险
41
风险偏高
动量
62
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
日内区间
当前US$72.46
52周区间
当前US$72.46
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 12.15亿 USD | 12.2亿 USD | 11.59亿 USD | 11.37亿 USD | 11.06亿 USD |
| 销货成本 | 4.16亿 USD | 4.29亿 USD | 3.89亿 USD | 3.67亿 USD | 3.49亿 USD |
| 毛利 | 7.99亿 USD | 7.9亿 USD | 7.7亿 USD | 7.7亿 USD | 7.56亿 USD |
| 研究与开发 | 9476.6万 USD | 9949.6万 USD | 9666.4万 USD | 9249.3万 USD | 8714万 USD |
| 销售、一般及管理费用 | 4.52亿 USD | 4.15亿 USD | 3.93亿 USD | 3.52亿 USD | 3.39亿 USD |
| 营业费用 | 5.47亿 USD | 6.88亿 USD | 5.63亿 USD | 4.71亿 USD | 4.6亿 USD |
| 利息收入 | — | 388.6万 USD | 332.3万 USD | 341万 USD | 79.4万 USD |
| 利息支出 | 540.5万 USD | 850.9万 USD | 1573.6万 USD | 1121.5万 USD | 1130.9万 USD |
| 折旧和摊销 | 9735.9万 USD | 1.1亿 USD | 1.12亿 USD | 1.07亿 USD | 1.01亿 USD |
| 营业利润 | 2.52亿 USD | 1.02亿 USD | 2.07亿 USD | 2.99亿 USD | 2.97亿 USD |
| 净利润 | 1.82亿 USD | 7340万 USD | 1.68亿 USD | 2.85亿 USD | 2.72亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$65.78
下跌空间 9.22%年度分割调整后的每股现金分配。
US$0.32
2025年(完整年度)0.0% 自从 2021
2026年(部分年度):US$0.32
US$0.32
2,021
US$0.32
2,022
US$0.32
2,023
US$0.32
2,024
US$0.32
2,025
US$0.32
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年8月24日 | US$0.08Irregular | 2026年8月24日 | 2026年9月4日 |
股息 | 2026年8月24日 | US$0.08Quarterly | 2026年8月24日 | 2026年9月4日 |
股息 | 2026年5月18日 | US$0.08Quarterly | 2026年5月18日 | 2026年5月29日 |
股息 | 2026年2月13日 | US$0.08Quarterly | 2026年2月16日 | 2026年2月27日 |
股息 | 2025年11月17日 | US$0.08Quarterly | 2025年11月17日 | 2025年11月28日 |
股息 | 2025年8月18日 | US$0.08Quarterly | 2025年8月18日 | 2025年8月29日 |
除息 2026年8月24日
US$0.08
Irregular
2026年8月24日登记 · 支付日 2026年9月4日
除息 2026年8月24日
US$0.08
Quarterly
2026年8月24日登记 · 支付日 2026年9月4日
除息 2026年5月18日
US$0.08
Quarterly
2026年5月18日登记 · 支付日 2026年5月29日
除息 2026年2月13日
US$0.08
Quarterly
2026年2月16日登记 · 支付日 2026年2月27日
除息 2025年11月17日
US$0.08
Quarterly
2025年11月17日登记 · 支付日 2025年11月28日
除息 2025年8月18日
US$0.08
Quarterly
2025年8月18日登记 · 支付日 2025年8月29日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T220.12亿0.02%129.35万亿 JPY0.09%JP¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI3.6亿0.02%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO3.01亿0.02%1.8万亿 USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB2.6亿0.14%1853亿 USD0.03%US$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP1.97亿0.20%977.83亿 USD0.20%US$213.04+0.55%
iShares Core S&P 500 ETFIVV1.51亿0.02%8964.4亿 USD0.03%US$781.97+0.60%
Vanguard Morningstar Small-Cap Growth ETFVBK1.5亿0.33%447亿 USD0.05%US$344.74+1.22%
State Street SPDR S&P 500 ETFSPY1.39亿0.02%8172亿 USD0.09%US$778.57+0.60%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Invesco S&P 500 Equal Weight ETFRSP
iShares Core S&P 500 ETFIVV
Vanguard Morningstar Small-Cap Growth ETFVBK
State Street SPDR S&P 500 ETFSPYAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。